SCHEMBL6183901

SCHEMBL6183901

COc1ccc(-c2nc(-c3ccc(C#N)cc3)n(O)c2-c2cccc(C)n2)cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 6/20 0.40
KIT P10721 2/20 0.38
PI4KB Q9UBF8 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
ALDH1A1 P00352 5/20 0.37
KDM4E B2RXH2 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6178736 0.92 TGFBR1 (0.38) KDM1AMEN1KMT2AATMALDH1A1
SCHEMBL6178729 0.85 MEN1 (0.38) MEN1KMT2AATM
SCHEMBL6180753 0.84 TGFBR1 (0.40) MEN1KMT2AATM
SCHEMBL6183430 0.78 TGFBR1 (0.41) MEN1KMT2AATM
SCHEMBL5500967 0.78 MAPK14 (0.49) KITMEN1KMT2A
SCHEMBL5107624 0.75 TGFBR1 (0.55)
SCHEMBL15256614 0.73 ALDH1A1 (0.55) MEN1KMT2AALDH1A1KDM4ENPC1
SCHEMBL6483937 0.70 TGFBR1 (0.40) ATMALDH1A1KDM4ENPC1RAB9A
SCHEMBL412530 0.70 ALDH1A1 (0.43) MEN1KMT2AALDH1A1KDM4ENPC1
SCHEMBL5497054 0.70 MAPK14 (0.49) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906089-B2 Triarylimidazole derivatives as cytokine inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2005-06-14 US disclosed
EP-1268465-B1 TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2005-06-01 EP disclosed
US-20030149277-A1 Triarylimidazole derivatives as cytokine inhibitors SMITHKLINE BEECHAM CORPORATION 2003-08-07 US disclosed
EP-1268465-A1 TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-01-02 EP disclosed
WO-2001072737-A1 TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149277-A1 Triarylimidazole derivatives as cytokine inhibitors IL2, IL2RA, IL6ST KDM1A 2356/4885KIT 136/4885PI4KB 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.